Edition:
United States

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

75.02USD
21 Apr 2017
Change (% chg)

$-0.68 (-0.90%)
Prev Close
$75.70
Open
$75.30
Day's High
$75.30
Day's Low
$74.68
Volume
214,275
Avg. Vol
185,446
52-wk High
$76.24
52-wk Low
$49.91

NUVA.OQ

Chart for NUVA.OQ

About

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $3,800.53
Shares Outstanding(Mil.): 50.66
Dividend: --
Yield (%): --

Financials

  NUVA.OQ Industry Sector
P/E (TTM): 109.47 33.88 29.95
EPS (TTM): 0.69 -- --
ROI: 2.81 12.79 13.21
ROE: 5.28 14.87 14.38

BRIEF-NuVasive announces FDA 510(K) clearance of Coroent small interbody system

* NuVasive - announced fda 510(K) clearance of coroent small interbody system indicated for intervertebral body fusion at contiguous levels in cervical spine Source text for Eikon: Further company coverage:

Mar 29 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

Bets on financials, pharma power U.S. hedge funds' strong start to year

NEW YORK, Feb 14 Several big-name U.S. hedge fund investors in the fourth quarter moved significant parts of their portfolios into financial and pharmaceutical stocks that are expected to benefit under the Trump administration, helping to power the sector to its best January performance in four years.

Feb 14 2017

BRIEF-Nuvasive sees FY 2017 revenue $1.065 bln

* Nuvasive inc - preliminary full year 2016 non-gaap operating profit margin expected to be in line with guidance of 16.0%

Jan 09 2017

BRIEF-Nuvasive repurchased about $49.6 mln in aggregate principal amount of its 2.75 PCT convertible senior notes due 2017

* Nuvasive-From Nov 11 to nov 28, repurchased about $49.6 million in aggregate principal amount of its 2.75% convertible senior notes due 2017 - SEC filing

Nov 28 2016

BRIEF-Jana Partners cuts sole share stake in Alphabet, takes sole share stake in Mondelez International

* Jana Partners LLC takes sole share stake of 111,127 shares in Sage Therapeutics Inc

Nov 14 2016

Federal Circuit affirms invalidity of NuVasive spine implant patent

A U.S. appeals court on Wednesday upheld a decision by a patent appeal board holding most of a NuVasive Inc spine implant patent invalid, which NuVasive continued to appeal despite having settled with the company that originally challenged the patent, Medtronic Plc.

Nov 10 2016

BRIEF-Nuvasive secures magnetic resonance FDA conditional clearance for Magec system

* Nuvasive secures magnetic resonance (mr) fda conditional clearance for magec system

Oct 27 2016

BRIEF-Nuvasive Q3 NON-GAAP Earnings Per Share $0.40

* Reiterated full year 2016 financial guidance in line with prior expectations, with exception of revenue

Oct 25 2016

More From Around the Web

Earnings vs. Estimates